Infectious disease Infections and Infestations
Conditions
Interventions
Participants will be allocated to intervention or control group in a 1:1 ratio, block-randomised by CCG. Those in the intervention group will be allocated to receive one of two different styles of int
(2) antibiotic feedback “reminder”, plus provision of link to evidence showing how feedback has been effective at changing antibiotic prescribing behaviour
(3) more information about the other data available at OpenPrescribing.net, potential cost savings highlighted, an example of another measure on which they rank poorly amongst other practices, and inv
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: GP practices in England (and any staff involved in prescribing therein) ranking in the worst 20% for prescribing broad-spectrum antibiotics
Exclusion criteria
Exclusion criteria: Practices must meet the following criteria: 1. Standard GP practices (Setting type 4) in England 2. At least one method of contact (postal address, fax number and/or email address) 3. Active status 4. Opened at least 6 months before start of trial 5. >= 500 registered patients 6. >= 1000 total items prescribed per month 7. >= 60 total antibiotic items prescribed in 6 months 8. Individual practices and whole CCGs not involved in preliminary testing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. ENGAGEMENT: Difference in the proportion of practices having their dashboard viewed during the 15 week intervention period, between intervention and control groups. Measured using data obtained from Google Analytics and other tracking systems for emails and questionnaire responses. Baseline period: 15 weeks prior to first intervention; follow-up period: 5 weeks following each wave, including day of sending (total 15 weeks). 2. PRESCRIBING: Difference in the proportion of antibiotics prescribed which were broad-spectrum, during the follow-up period, between intervention and control groups. Measured using publicly available prescribing data published by NHS Digital. Baseline period: latest available six months of data at start of study; follow-up period: corresponding six month period, one year on from baseline period. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. ENGAGEMENT, measured using data obtained from Google Analytics and other tracking systems for emails and questionnaire responses. Baseline period: 15 weeks prior to first intervention; follow-up period: 5 weeks following each wave, including day of sending (total 15 weeks) 1.1. Difference in the proportion of practices having their dashboard viewed during the 15 week intervention period, and in the proportion of broad-spectrum antibiotics prescribed, between groups A and B 1.2. Difference in the mean dashboard views per practice during the 15 week intervention period, for intervention versus control groups, and for group A versus B 1.3. Number of practices accessing at least one link provided in the intervention, as a proportion of all practices contacted, for group A versus B 1.4. Number of links accessed at least once as a proportion of all links delivered by each method of contact (email, fax, letter) 1.5. Proportion of emails opened overall; and total number of links accessed from emails as a proportion of those opened, during the follow-up period, for intervention A versus B 1.6. Exploratory descriptive analysis of browsing sessions arising from each link accessed: number of browsing sessions, number of different IP addresses, and number of pages viewed per session (to explore sharing of links among professionals) 2. PRESCRIBING, measured using publicly available prescribing data published by NHS Digital. Baseline period: latest available six months of data at start of study; follow-up period: corresponding six month period, one year on from baseline period 2.1. From the primary outcome measure the overall effect of the intervention will be estimated on the number of broad-spectrum antibiotics prescribed during the follow-up period. This will be calculated as the total difference between the observed number of broad-spectrum antib | — |
Countries
United Kingdom
Outcome results
None listed